Objective:To study the short-term effects,toxic side effects and immune function of Aidi injection adjuvant GP methods chemotherapy for advanced non-small cell lung cancer(NSCLC).Methods:130 patients with advanced NSCLC were divided into study group and the control group according to treatment methods.The study group were given Aidi injection +GP,and the control group only treated with GP.The short-term effects,toxic side effects gradeⅢ-Ⅳand immune function changes were compared between the two groups.Results:The overall response rate was 40.28%in study group,higher than 37.93% in control group(P>0.05).The two groups showed differences in the rates of leucocyte decrease,gastrointestinal reaction and platelets decrease(P<0.05).The levels of CD4,CD8 and CD4/CD8 didn′t changed obviously in study group(P>0.05),while in the control group the levels of CD4,CD8 and CD4/CD8 changed more significantly than before(P<0.05).The two groups also produced differences in CD4,CD8 and CD4/CD8 after treatment( P<0.05 ) .Conclusion: The short-term effects of Aidi injection adjuvant GP chemotherapy regimen for advanced NSCLC is similar to only GP chemotherapy,but it can obviously reduce the incidence of toxic side effects and prevent the immune func-tion.

Objective To investigate the effect of lapatinib mesylate tablets in the patients with advanced non-small cell lung cancer. Methods A total of 55 patients with advanced non-small cell lung cancer who were given chemoth·erapy in our hospital from January 2015 to May 2017 were selected. Among them, 27 patients who were given paclitaxel combined with cisplatin for treatment were assigned to the conventional group. 28 patients who were given apatinib mesylate for treatment were assigned to the intervention group. The patient's therapeutic effect, related index changes, adverse reactions and quality of life were observed. Results ORR, DCR, total incidence rate of adverse reactions and quality of life in the intervention group were higher than those in the conventional group (P<0.05); the levels of CEA, VEGF and MMP-9 in the two groups after treatment were lower than those before treatment (P<0.05). Patients in the intervention group had lower levels of CEA, VEGF, and MMP-9 after treatment (P<0.05). Conclusion The clinical effect of lapatinib mesylate in the treatment of advanced non-small cell lung cancer is significant.